gnaumov9
- Oct 13
- 1 min read

RS ONCOLOGY PRESENTS POSTERS AT INTERNATIONAL CONFERENCE

Updated: Oct 13

AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS - BOSTON, MA

Our Chief Scientist, Brian Cunniff, presented "Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial "

AACR 2023 poster_Tri_FINAL

.pdf

Download PDF • 2.35MB

Recent Posts

See All

Top 10 Questions to Ask Your Doctor About Your Malignant Mesothelioma Cancer Diagnosis

Malignant Mesothelioma can be confusing and devastating. Pronouncing “Mesothelioma” is a challenge, as is the disease. You are your best advocate in any health situation, and preparing a list of quest

RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreve

Cambridge, Mass., Sept 12, 2023 – RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of th

RS ONCOLOGY PRESENTS POSTERS AT INTERNATIONAL CONFERENCE

Recent Posts

Subscribe to our newsletter • Don’t miss out!